WallStreetZenWallStreetZen

NASDAQ: CTKB
Cytek Biosciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for CTKB

Based on 4 analysts offering 12 month price targets for Cytek Biosciences Inc.
Min Forecast
$7.00-23.5%
Avg Forecast
$9.00-1.64%
Max Forecast
$10.00+9.29%

Should I buy or sell CTKB stock?

Based on 4 analysts offering ratings for Cytek Biosciences Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
0 analysts 0%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTKB stock forecasts and price targets.

CTKB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-29
lockedlocked$00.00+00.00%2023-12-14
lockedlocked$00.00+00.00%2023-11-09
lockedlocked$00.00+00.00%2023-10-16

1 of 1

Forecast return on equity

Is CTKB forecast to generate an efficient return?
Company
N/A
Industry
20.28%
Market
28.92%

Forecast return on assets

Is CTKB forecast to generate an efficient return on assets?
Company
N/A
Industry
10.59%

CTKB revenue forecast

What is CTKB's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$218.9M+19.55%
Avg 2 year Forecast
$261.6M+42.84%
CTKB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTKB revenue growth forecast

How is CTKB forecast to perform vs Medical Devices companies and vs the US market?
Company
19.55%
Industry
7.5%
Market
37.91%
CTKB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTKB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTKB vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CTKB$9.15$9.00-1.64%Strong Buy
ESTA$44.11$50.00+13.35%Strong Buy
PACB$5.19$10.88+109.54%Buy
AHCO$10.52$11.30+7.41%Buy
QTRX$27.00$33.00+22.22%Strong Buy

Cytek Biosciences Stock Forecast FAQ

Is Cytek Biosciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CTKB) stock is to Strong Buy CTKB stock.

Out of 4 analysts, 3 (75%) are recommending CTKB as a Strong Buy, 0 (0%) are recommending CTKB as a Buy, 1 (25%) are recommending CTKB as a Hold, 0 (0%) are recommending CTKB as a Sell, and 0 (0%) are recommending CTKB as a Strong Sell.

If you're new to stock investing, here's how to buy Cytek Biosciences stock.

What is CTKB's revenue growth forecast for 2024-2025?

(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 19.55% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 37.91%.

Cytek Biosciences's revenue in 2024 is $183,117,000.On average, 3 Wall Street analysts forecast CTKB's revenue for 2024 to be $29,674,420,794, with the lowest CTKB revenue forecast at $26,974,281,646, and the highest CTKB revenue forecast at $33,411,510,969.

In 2025, CTKB is forecast to generate $35,454,236,720 in revenue, with the lowest revenue forecast at $31,420,293,897 and the highest revenue forecast at $41,208,298,308.

What is CTKB's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: CTKB) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 10.59%.

What is CTKB's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CTKB price target, the average CTKB price target is $9.00, with the highest CTKB stock price forecast at $10.00 and the lowest CTKB stock price forecast at $7.00.

On average, Wall Street analysts predict that Cytek Biosciences's share price could fall to $9.00 by Feb 28, 2025. The average Cytek Biosciences stock price prediction forecasts a potential downside of 1.64% from the current CTKB share price of $9.15.

What is CTKB's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: CTKB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.